NCT00630409View on ClinicalTrials.gov

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Gemcitabine

800 mg IV day 1 and 8

DRUG

Doxil

24 mg/m2 every 21 days IV

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

University of Pittsburgh

OTHER

NCT00630409 - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter